| Stockholders' Equity Note Disclosure [Text Block] |
The company has authorized share capital of an unlimited number of common voting shares. | | (i) |
2018 At-The-Market (“ATM”) Facility | | | | | | | | On March 28, 2018, the Company entered into an “At-The-Market” Facility (“ATM”) equity distribution agreement with Cantor Fitzgerald acting as sole agent. Under the terms of this facility, the Company may, from time to time, sell shares of our common stock having an aggregate offering value of up to $30 million through Cantor Fitzgerald on the Nasdaq Capital Market. During the year ended December 31, 2018, the Company issued 4,085,615 shares under this ATM equity facility at an average price of $2.71 for gross proceeds of $11 million ($10.7 million net of share issue costs). Costs associated with the proceeds consisted of a 3% cash commission. | | | | | | | (ii) |
2017 Share purchase agreement | | | | | | | | On October 27, 2017, we entered into the 2017 Aspire Purchase Agreement, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $15,500,000 of Common Shares over approximately 30 months. During the year ended December 31, 2017 and pursuant to the terms of the Aspire Purchase Agreement, Aspire Capital purchased 357,143 Common Shares for gross proceeds of $500 thousand ($324 thousand net of cash share issue costs) and we also issued 321,429 Common Shares to Aspire Capital in consideration for entering into the Aspire Purchase Agreement. During the year ended December 31, 2018, the Company issued 5,231,953 common shares under the Aspire Purchase Agreement at an average price of $2.87 per share for gross and net proceeds of approximately $15 million. On a cumulative basis to December 31, 2018, the Company has raised a total of $15.5 million gross proceeds under the Aspire Purchase Agreement, the total amount that was available under the Agreement. | | | | | | | (iii) |
2018 Share Purchase Agreement | | | | | | | | On May 30, 2018, the Company entered into the 2018 Aspire Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $20 million of Common Shares over approximately 30 months. Pursuant to the terms of this agreement, on June 8, 2018, the Company issued 170,261 Common Shares (“Commitment Shares”) to Aspire Capital in consideration for entering into the 2018 Aspire Purchase Agreement. The Company recorded $600 thousand in general and administrative expenses related to the issuance of the Commitment Shares. During the year ended December 31, 2018, the Company issued 907,547 shares under the 2018 Aspire Purchase Agreement at an average price of $2.12 per share for gross and net proceeds of approximately $1.9 million. | | | | | | | (iv) | At-The-Market (“ATM”) Facility | | | | | | | | On April 2, 2015, Aptose entered into an at-the-market (“ATM”) equity facility with Cowen and Company, LLC, acting as sole agent. Under the terms of the ATM, Aptose was permitted to sell Common Shares having an aggregate offering value of US$20,000,000 on NASDAQ. During the year ended December
31, 2017, the Company issued 10,952,093 common shares under the ATM at an average price of $1.27 per share for gross proceeds of $13.9 million ($13.4 million net of share issue costs). Costs associated with the proceeds included a 3% cash commission. The ATM expired on December 29, 2017 and as at that date the Company had issued a cumulative $20,000,000 of Common Shares pursuant to this facility. | Loss per common share is calculated using the weighted average number of common shares outstanding and is presented in the table below: | (in thousands) | | | Year ended
Dec 31, 2018 | | | | Year ended
Dec 31, 2017 | | | | | | | | | Net loss | | $ | (28,868 | ) | | $ | (11,643 | ) | | Weighted-average common shares – basic and diluted | | | 33,391 | | | | 22,313 | | | Net loss per share – basic and diluted | | $ | (0.86 | ) | | $ | (0.52 | ) | The effect of any potential exercise of the Company’s stock options outstanding during the year has been excluded from the calculation of diluted loss per common share as it would be anti-dilutive.
|